Gubra A/S GUBRA.CO
Nasdaq Copenhagen · Healthcare · Biotechnology
302.40 DKK
+1.8%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Gubra
| DKK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 199 | 205 | 266 | 2,637 |
| EBITDA | 15 | −28 | −20 | 2,178 |
| Net income | 4 | −45 | −36 | 1,691 |
| Balance sheet | ||||
| Equity | 108 | 480 | 451 | 1,146 |
| Total debt | 69 | 71 | 96 | 107 |
| Cash | 72 | 53 | 134 | 32 |
| Net debt | −3 | 18 | −38 | 75 |
| Ratios and per share | ||||
| EBITDA margin | 7.4% | −13.7% | −7.5% | 82.6% |
| Profit margin | 2.2% | −21.7% | −13.7% | 64.1% |
| Return on equity | 4.0% | −9.3% | −8.1% | 147.5% |
| Earnings/share (DKK) | 0.26 | −2.73 | −2.24 | 103.51 |
| Book value/share (DKK) | 6.62 | 29.44 | 27.63 | 70.16 |
| Shares outstanding (M) | 16 | 16 | 16 | 16 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 2.9 |
| P/B | 4.3 |
| EV / EBITDA | 2.3 |
| Net debt / EBITDA | 0.0 |
| Return on equity | 147.5% |
| Profit margin | 64.1% |
| Beta 1Y | 1.22 |
| Revenue growth 1Y | +892.2% |
| Revenue CAGR 3Y | +136.5% |
| Earnings/share CAGR 3Y | +632.3% |
| ROE avg. 3Y | 43.4% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (DKK)
| 2025 | 61.20 |
Not investment advice. Figures may contain errors from the data source.